Apoptotic Cell Clearance in Homeostasis and Inflammation {#s1}
========================================================

The controlled elimination of cells during development allows the remodeling of tissues and organs to purpose them for specialized functions (reviewed in [@B37]). In fully formed adult organisms, it is estimated that approximately 50 million cells are deleted by apoptosis every hour, providing a mechanism for homeostatic self-renewal ([@B110]). Apoptosis also has an important role in the responses to injury or infection, controlling the numbers of inflammatory cells present at inflamed sites ([@B127]), shaping the repertoire of effector lymphocyte populations ([@B4]), and determining the capacity for repair and regeneration of tissue following injury ([@B12]). Importantly, the consequences of cell death are ultimately defined by the mechanism(s) by which apoptotic cells (AC) are removed from tissues ([@B136]). Thus, the molecular pathways involved in recognition and subsequent phagocytosis of AC will determine whether apoptotic cell clearance is immunologically "silent" or even anti-inflammatory. By implication, breakdown or failure of normal AC removal mechanisms will increase the tissue load of AC and secondarily necrotic cells and has the potential to drive the aberrant tissue repair responses and failure to restore tissue integrity ([@B29]).

The efficient clearance of AC from tissues requires that AC are specifically recognized and destroyed, either by neighboring cells or by specialized phagocytes ([@B45]). Although AC retain plasma membrane integrity, alterations in composition of the membrane lipids, carbohydrates, and proteins provide molecular cues that mark them for recognition by other cells. In particular, translocation of anionic phospholipids \[phosphatidylserine (PtdSer) and phosphatidylethanolamine\] from the inner leaflet to the outer leaflet of the plasma membrane represents one of the hallmarks of apoptosis ([@B141]). Exposure of PtdSer on the outer leaflet of the plasma membrane can be detected directly *via* specific PtdSer receptors (see below). Alternatively, binding of proteins that act to "opsonize" the AC membrane enables indirect engagement of additional receptor pathways for the recognition and internalization of AC ([@B144]; [@B119]). Additional changes in glycosylation ([@B67]; [@B47]), crosslinking ([@B125]), or proteolytic shedding of proteins ([@B32]) on the AC surface provide additional "apoptotic cell associated molecular patterns" that also influence AC recognition ([@B46]). The repertoire of phagocyte receptors that are engaged during recognition and subsequent internalization of AC may determine the subsequent response of the phagocytic cell.

Molecular Mechanism of AC Clearance {#s2}
===================================

There are many different receptor families involved in the process of phagocytosis of AC \[extensively reviewed elsewhere ([@B37]; [@B51]; [@B110]; [@B89]), summarized in [**Table 1**](#T1){ref-type="table"}\]. Genetic deletion of a single receptor pathway seldom eliminates phagocytic clearance capacity, suggesting a level of functional redundancy in AC clearance, both *in vitro* and *in vivo*. AC clearance pathways may have multiple, partially overlapping physiological roles, as the extent to which specific deletion impacts upon homeostasis and immune processes *in vivo* differs ([@B60]). However, adaptation to universal gene deletion may complicate interpretation and studies of inducible knockouts will provide important additional insights into the role of specific molecular pathways that are involved in AC clearance *in vivo*.

Receptors mediating AC phagocytosis can be broadly divided into non-opsonic (direct recognition) or opsonic receptors (indirect recognition). The receptors mediating AC clearance can be further categorized based on their potential for transducing signals that control the internalization of AC ([@B10]). For example, although T cell immunoglobulin and mucin domain containing 4 (TIM4) and brain-specific angiogenesis inhibitor 1 (BAI-1) are both capable of mediating recognition of PtdSer, only BAI-1 is capable of directly mediating signal transduction ([@B122]; [@B121]). For a single phagocyte, efficient phagocytosis may require cooperative activity of receptors involved in AC clearance. Optimal phagocytic responses may require the establishment of a phagocytic synapse with spatial co-localization of molecules of similar dimensions at the interface between phagocyte and target, together with exclusion of phosphatases such as CD45 or CD148 ([@B10]).

###### 

Summary of key molecular pathways mediating apoptotic cell phagocytosis. Examples of molecules mediating either direct or indirect (*via* bridging molecules) recognition of apoptotic cells, together with putative signaling mechanisms that are triggered ([@B138]; [@B137]; [@B144]; [@B106]; [@B147]; [@B5]; [@B140]; [@B145]; [@B122]; [@B132]; [@B124]; [@B150]; [@B119]; [@B121]; [@B111]; [@B128]; [@B77]).

  ----------------------------------------------------------------------------------------------------------
  Receptor                   Ligand                  Signaling
  -------------------------- ----------------------- -------------------------------------------------------
  **Direct recognition**                             

  BAI-1                      PtdSer                  GPCR -- DOCK180, ELMO, Rac-1 ([@B122])

  TIM-4                      PtdSer                  Indirect *via* integrins ([@B121])

  CD300                      PtdSer                  ITIM ([@B111])

  Stabilin-2/MEGF-10         PtdSer                  *via* GULP ([@B124])

  **Indirect recognition**                           

  MER                        PROS1, GAS6 ([@B144])   Autophosphorylation, Akt, PLCγ2, FAK, Rac-1 ([@B150])

  AXL                        Gas6                    IFNAR, STAT1, SOCS1/3 ([@B132])

  SCARF ([@B128])            C1q ([@B119])           

  Integrin αMβ2 ([@B106])    C1q                     

  Integrin αvβ5              MFG-E8\                 FAK, DOCK180, Rac-1 ([@B3]; [@B5])
                             Del-1                   

  Integrin αvβ3              MFG-E8\                 CRKII, DOCK180, Rac-1 ([@B64]; [@B138]; [@B137])
                             Del-1\                  
                             TSP-1                   

  CD36                       TSP-1                   Fyn, Pyk2 ([@B145])
  ----------------------------------------------------------------------------------------------------------

([@B138]; [@B137]; [@B144]; [@B106]; [@B5]; [@B64]; [@B3]; [@B122]; [@B132]; [@B145]; [@B119]; [@B124]; [@B150]; [@B121]; [@B111]; [@B128])

Regulation of Apoptotic Cell Clearance {#s3}
======================================

Phagocytosis of AC may be regulated rapidly (within minutes) in response to exogenous or microenvironmental signals *via* changes in the ligand binding activity of receptors. Alternatively, the spatial distribution of receptors that mediate AC uptake may result in the formation of receptor micro-clusters that facilitate phagocytosis, as has been demonstrated for FcgR ([@B92]). Phagocytosis of AC may also be controlled over a more prolonged time frame *via* changes in the repertoire of receptors that are expressed on the phagocyte membrane. For receptors that recognize AC [*indirectly*]{.ul} through "bridging" ligands that bind to the AC, the availability of those ligands represents another level of control. Increased AC phagocytosis has been shown to occur following crosslinking of CD44 ([@B68]) or in the presence of soluble mediators such as galectin-3 ([@B13]); here we consider some of the key factors that exert control of AC phagocytosis and whether the underlying mechanisms of regulation could be exploited for therapeutic gain (summarized in [**Table 2**](#T2){ref-type="table"}).

###### 

Summary of key mechanisms by which apoptotic cell phagocytosis is regulated. Examples of mediators that act to regulate phagocytosis of apoptotic cells, including putative mechanisms that are involved in regulation.

  Regulatory pathway                    Mechanism
  ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  LipoxinA4                             FPR mediated activation of myosin IIa, Rho, Rac-1, cdc42 (Reville et al., 2006; Maderna et al., 2010)
  Resolvin E1 (RvE1)                    ERV-1/ChemR23 (Akt and ribosomal S6 protein phosphorylation) (Pirault and Bäck, 2018; Ohira et al., 2010), \*BLT1 sequestration (Arita et al., 2007)
  D series Resolvins (D1, D2, D3, D5)   GPR32, GPR18 (PKA, STAT3), ALX/FPR2 (Pirault and Bäck, 2018; Krishnamoorthy et al., 2010)
  Maresin 1 (MaR1)                      \*Inhibition of LTAH~4~ (Dalli et al., 2013)
  Del-1                                 RGD-dependent binding to integrins (Kourtzelis et al., 2019)
  Osteopontin                           Competition for integrin ligand binding (Sakamoto et al., 2016)
  Fibronectin                           Scaffold for TIM-4 (Lee et al., 2018), β1 integrin-dependent signaling (McCutcheon et al., 1998)
  Fibronectin and CD31                  Activation of integrin α5β1 and FN-dependent uptake (Vernon-Wilson et al., 2006)
  Glucocorticoids                       Upregulation of MER expression and activation (McColl et al., 2009; Zagórska et al., 2014)
  Glucocorticoids                       Cytoskeletal regulation (Rac-1) (Giles et al., 2001)
  LXR agonists                          Upregulation of phagocytic receptors inc. Mer (A-Gonzalez et al., 2009)
                                        
  CD44 cross-link                       Cytoskeletal regulation (Hart et al., 2012), Membrane picket formation (Freeman et al., 2018)
  CD14 cross-link                       Mer phosphorylation (Zizzo and Cohen, 2018)
  Galectin-3                            Cytoskeletal regulation (Erriah et al., 2019)
  CD47                                  SIRPα--ITIM mediated SHP1 and SHP2 activation (Barclay and Van den Berg, 2014; Okazawa et al., 2005)

\*Additional anti-inflammatory effects ([@B66]; [@B105]; [@B59]; [@B57]; [@B117]; [@B129]; [@B156]; [@B1]; [@B103]; [@B116]; [@B68]; [@B78]; [@B161]; [@B9]; [@B158]; [@B134]; [@B52]; [@B83]; [@B86]; [@B126]; [@B160]; [@B38]; [@B77]).

Lipid-Derived Mediators {#s4}
=======================

Multiple studies have demonstrated the contribution of lipid mediators to the control of phagocytosis, shown schematically in [**Figure 1**](#f1){ref-type="fig"}. The lipoxin family of lipids, derived from arachidonic acid, were shown to have anti-inflammatory effects that impact on the resolution phase of inflammation. Lipoxin A4 (LXA~4~) stimulates phagocytosis of AC ([@B59]), acting *via* the G-protein coupled receptor (GPCR) formyl peptide receptor 2 (FPR2) to induce Rho, Rac, cdc42-dependent actin-cytoskeleton rearrangements ([@B97]). Both FPR1 and FPR2 confer recognition of *N*-formylated peptides generated during bacterial and mitochondrial protein synthesis and are abundantly expressed on leukocytes. Although FPR1 signaling activates pro-inflammatory signaling ([@B31]), certain FPR2 agonists elicit anti-inflammatory responses in innate immune cells (e.g., LXA~4~, Annexin A1, Ac2-26) ([@B139]; [@B41]), suggesting a specific role for FPR2 in controlling phagocyte responses during resolution of inflammation. Interestingly, in a mouse model of arthritis, genetic deletion of FPR2 abrogated the pro-resolving effects of RvD3 ([@B8]).

![Schematic representation of mechanisms promoting macrophage phagocytosis of AC by lipid mediators. In addition to a role in recognition of N-formylated peptides that are generated during bacterial and mitochondrial protein synthesis, the formyl peptide receptor 2 (ALX/FPR2) also binds to Lipoxin A4, Annexin A1, and Ac2-26 (N-terminal part of Annexin A1) to increase macrophage phagocytosis of AC ([@B59]; [@B96]; [@B139]; [@B97]). Signaling following ALX/FPR2 binding by these ligands was shown to induce rearrangements in the actin cytoskeleton in a Rho, Rac, and cdc42-dependent manner. GPR32 is thought to be the main receptor for the resolvin D family members 1, 3, and 5 (RvD1,3,5) that acts to promote phagocytosis of AC and reduce NF-κB activity. RvD1 and RvD3 were also found to bind ALX/FPR2 with high affinity and induce macrophage phagocytosis ([@B7]; [@B79], [@B78]; [@B26]). The resolving E family member 1 (RvE1) increased macrophage phagocytosis of AC *via* binding to ERV-1/ChemR23. Phosphorylation of Akt and S6 proteins induced cytoskeletal rearrangements as well as promotion of transcription of the anti-inflammatory cytokine IL-10 ([@B83]). RvE1 can also competitively bind to the leukotriene B4 receptor BLT4, acting to reduce pro-inflammatory signaling ([@B7]; [@B116]; [@B83]). Resolvin D2 (RvD2) mediated activation of GPR18 induced an M2-like macrophage phenotype exhibiting increased phagocytosis *via* a mechanism involving phosphorylation of the ERK, PKA, and STAT3 ([@B49]; [@B26]). Although resolving E2 (RvE2) was also reported to induce macrophage phagocytosis, the pathway that controls this effect has not been clearly identified ([@B115]).](fphar-10-00891-g001){#f1}

The resolvin family of anti-inflammatory/pro-resolution lipids derived mainly from omega-3 fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), includes the E-series of the anti-inflammatory lipid mediators, resolvin-E1 (RvE1) and resolvin-E2 (RvE2) ([@B75]), and the D-series resolvins ([@B58]). These mediators actively promote resolution of inflammation *via* a number of mechanisms, including down-regulation of NF-κB signaling and dampening the effects of pro-inflammatory mediators ([@B7]). Resolvins also promote phagocytosis by binding to various GPCRs. RvE1 binding to ChemR23 on macrophages enhances macrophage phagocytosis of zymosan particles *via* a mechanism involving enhanced Akt and ribosomal protein S6 phosphorylation ([@B116]; [@B83]).These effects are similar to the rapid increase in phagocytosis of AC and zymosan particles that is induced by the natural peptide ligands for ChemR23 such as chemerin ([@B21]). Similarly, RvE2 has also been reported to promote phagocytosis of zymosan, though it may act through a different repertoire of GPCR from RvE1 ([@B115]).

The resolvin D-series (RvD1-5) lipids have also been demonstrated to have anti-inflammatory effects on leukocyte recruitment and production of anti-inflammatory cytokines, including IL-10. RvD lipids also act to increase phagocytosis *via* the action of different GPCR ([@B126]). RvD3 and RvD1 act *via* GPR32 to increase macrophage phagocytosis of AC and zymosan. RvD1 also promotes phagocytosis *via* the FPR2 ([@B78]), which had been shown to regulate AC clearance by lipoxin A4 ([@B97]). Macrophage phagocytosis of zymosan, *E. coli* ([@B143]), and AC was increased by RvD2 both *in vitro* and *in vivo* ([@B22]). Analysis of downstream signaling suggested a mechanism in which RvD2 acted on GPR18 to regulate PKA and STAT3 ([@B49]; [@B24]; [@B23]).

Another class of specialized pro-resolving lipid-derived mediators that also modulate macrophage phagocytosis of AC are the maresins ([@B142]). In addition to increasing macrophage phagocytosis of AC in a similar manner to RvD1, maresin 1 (MaR1) was also shown to reduce neutrophil infiltration and to promote tissue regeneration as well as inhibiting leukotriene A~4~ hydrolase (LTA~4~H) activity, shifting macrophages toward a pro-resolution phenotype ([@B27]).

In summary, the activity of specialized pro-resolving lipid-derived mediators (SPM) activity peaks during the resolution phase of inflammation. High affinity interactions between different SPM and their receptors (e.g., RVD1/3-ALX/FPR2) suggest that there may be synergistic activity of SPM during the resolution phase of inflammation. In terms of regulation of phagocytic function, specific SPM-receptor interactions lead to the phosphorylation of proteins that are involved in the regulation of cytoskeletal organization that are also required for cell migration. As a consequence, neutrophil transmigration was reduced following treatment with SPM (e.g., RvD1, MaR1) together with increased evidence of tissue regeneration. In addition, inhibition of the pro-inflammatory effects of LTB~4~ mediated by the LTB~4~ receptor, BLT1, was induced by RvE1 and MaR1. Thus, the effects of pro-resolving lipid mediators are not restricted to phagocytosis of AC, in keeping with a broader role during resolution of inflammation and restoration of tissue homeostasis.

Extracellular Matrix---Integrins and Their Ligands {#s5}
==================================================

A role for integrin αVβ3 in AC clearance by macrophages was first demonstrated in 1990 ([@B138]), and induction of expression of αV ([@B6]) and partnering β subunits \[β3 ([@B138]) and β8 ([@B80])\] during *in vitro* macrophage differentiation confers the capacity for uptake of AC *via* bridging factors such as thrombospondin-1 or MFG-E8 ([@B3]). Another αV ligand that promotes phagocytosis of AC and acquisition of a pro-resolving macrophage phenotype is Del-1, an RGD-containing secreted molecule ([@B77]) that binds to AC ([@B64]). Deletion of Del-1 results in reduced expression of many genes associated with regulation of inflammation including liver X receptor (LXR), TGF-β1, ATP-binding cassette transporter 1 (ABCA1), transglutaminase 2, Axl, CD36, and uncoupling protein 2. Integrin-dependent phagocytosis of AC can be inhibited by addition of soluble αVβ3 ligands (fibronectin or vitronectin) ([@B138]), or direct competitors of αV ligand binding such as HMBG1 ([@B54]). Molecules that bind directly to αVβ5 such as histone H3 also inhibited AC phagocytosis ([@B53]).

However, rapid regulation of integrin-dependent cellular interactions may also occur as a result of outside-in signaling ([@B70]). Integrin-dependent signaling also regulates AC phagocytosis. For example, osteopontin acts to block αV/MFG-E8-mediated engulfment *via* prevention of dissolution of the actin cup that is formed beneath bound apoptotic targets, thereby prolonging diffuse Rac activation ([@B134]). Inhibition of integrin-dependent Rac1 or ROCK signaling was associated with reduced phagocytosis of ACs and fibronectin-coated beads in mice lacking α8 integrins, with delayed healing in a model of glomerulonephritis ([@B100]). Association of TIM4 with αVβ3 acts to potentiate AC phagocytosis. Fibronectin was identified as a TIM-4 binding partner, providing a scaffold to bring TIM-4 and integrins together to facilitate phagocytosis ([@B86]). Consequently, disruption of TIM-4 interaction with fibronectin causes a reduction in TIM-4-dependent phagocytosis, possibly as a result of altered integrin signaling ([@B42]). Albert and colleagues demonstrated that aVβ5 formed a complex with Crk/DOCK180 and Rac, homologues of the key phagocytic module (Ced-2, 5 and 10) identified in *C. elegans* ([@B5]).

Other integrins may also be important regulators of AC phagocytosis. Increased phagocytosis of ACs was observed following adhesion to extracellular matrix ligands in a manner that was partially dependent on b1 integrin activity ([@B105]). The extent of integrin-dependent adhesion and signaling may be critical, since interaction with extracellular matrix modified by cigarette smoke resulted in reduced AC clearance, possibly due to sequestration of integrins involved in phagocytosis or cytoskeletal regulation ([@B73]; [@B107]; [@B153]). Similarly, reduced phagocytosis and pro-inflammatory cytokine production were reported following exposure of macrophages to bushfire smoke extract ([@B63]). Fibronectin may also have an important role in the selective engulfment of AC following CD31 ligation. Although CD31 mediates tethering of both AC and viable cells, CD31-dependent activation of phagocyte α5β1 facilitated specific phagocytosis of ACs *via* a fibronectin bridge ([@B156]).

Integrins also have a key role in the regulation of phagocytosis by controlling the localization of key molecules such as the phosphatase, CD45 ([@B50]). In their elegant studies, Freeman and colleagues showed that engagement of FcγR increased the lateral membrane mobility of CD45 due to loss of cytoskeletal constraint, yet CD45 was found to be excluded from the nascent phagocytic cup *via* an integrin-dependent barrier. The depletion of CD45 from the phagocytic-target interface was shown to facilitate phagocytosis. Thus, the formation of an integrin-dependent diffusional barrier acted to increase the efficiency of phagocytosis at low levels of opsonization ([@B50]). We reported that cross-linking of macrophage CD44 acted to rapidly augment phagocytosis of apoptotic neutrophils ([@B66]). Although the mechanism remains to be fully defined, cytoskeletal reorganization observed following CD44 cross-linking, including Rac activation, altered podosome formation, and migratory capacity ([@B68]), would be consistent with changes in the extent of CD44-dependent restriction of lateral membrane receptor movement ([@B52]).

Ligation of other macrophage receptors may also act to increase phagocytosis of ACs. Zizzo and Cohen demonstrated that antibody-induced cross-linking of CD14 promoted phosphorylation of Mer receptor tyrosine kinase (Mer) and potentiated phagocytosis of ACs ([@B160]). The presence of exogenous beta galactoside binding lectin, galectin-3, acts to promote phagocytosis of ACs ([@B38]), possibly *via* cross-linking of the integrin αVβ3 ([@B71]). Galectin-3 has also been reported to bind to Mer ([@B13]).

Recognition of PtdSer *via* Tyro3, Axl, and Mer Receptor Tyrosine Kinases {#s6}
=========================================================================

Mer and the related receptor tyrosine kinases Tyro3 and Axl enable phagocytes to recognize PtdSer exposed on the surface of AC *via* binding to the PtdSer opsonins Protein S and Gas6 ([@B88]). Although signaling downstream of Mer promotes cytoskeletal rearrangements that are necessary for internalization ([@B150]), Mer signaling also has an important role in the resolution of inflammation by driving production of specialized resolving mediators, including LxA4 and RvD1 ([@B16]; [@B14]). Mer-deficient mice exhibit impaired phagocytosis of ACs contributing to development of allergic inflammation ([@B40]), atherosclerosis ([@B148]), or autoimmune diseases ([@B133]). Proteases that are likely present at sites of inflammation can reduce the activity of Mer. Specific cleavage of Mer from the phagocyte surface was demonstrated to be mediated by ADAM17 ([@B149]) reduced AC phagocytosis and may represent a key mechanism controlling AC clearance capacity during progression of inflammatory responses ([@B87]; [@B15]). In addition, the presence of soluble Mer may compete for phagocyte binding to protein S or Gas6 opsonized AC, decreasing Mer-dependent phagocytosis as a consequence ([@B135]). Inhibition of proteolytic cleavage of Mer was shown to ameliorate LPS-induced lung injury ([@B87]), and in animals expressing a cleavage-resistant form of Mer, inflammation-mediated tissue damage was reduced with improved resolution of inflammation ([@B28]).

Regulation of AC Phagocytosis by Glucocorticoids {#s7}
================================================

The capacity for phagocytosis of AC is altered during differentiation and activation of macrophages. In particular, acquisition of a macrophage phenotype associated with tissue repair correlates with increased phagocytosis of AC. For example, glucocorticoids (including methylprednisolone, hydrocortisone, and dexamethasone) are potent drivers for the engulfment of AC ([@B91]; [@B57]), inducing marked changes in the receptor expression profile of macrophages. Over 100 genes have been shown to be modulated by glucocorticoids including receptors involved in phagocytosis of ACs such as CD163, FPR1, and Mer ([@B35]). Glucocorticoid-mediated alterations in the macrophage phenotype also include inhibition of release of pro-inflammatory cytokines together with anti-inflammatory cytokine production (e.g. TGFβ, IL-10 and IL-1ra), thereby promoting tissue repair and regeneration. In addition, downregulation or reduced phosphorylation of key integrin signaling molecules such as paxillin, pyk2, and p130Cas ([@B57]) may limit focal adhesion formation, allowing integrins to participate in phagocytosis of ACs. In addition, glucocorticoid-induced upregulation of expression of the integrin ligand MFG-E8 may further contribute to augmentation of AC phagocytosis. Deficiency of MFG-E8 or knockdown with RNAi reduced the extent of AC phagocytosis following treatment with glucocorticoids ([@B84]). Augmented AC phagocytosis following glucocorticoid treatment was shown to be primarily dependent on Mer and the Mer ligand, protein S ([@B103]; [@B161]). Increased expression of Mer following glucocorticoid treatment confers the capacity for tethering and subsequent phagocytosis of AC by macrophages ([@B33]). In keeping with these findings, increased phagocytosis of apoptotic cells following GC treatment was not observed in macrophages from Mer knockout mice ([@B158]). The increased protein S-dependent phagocytosis of AC by macrophages following glucocorticoid treatment was shown to be reversed by interferon-γ ([@B69]). This observation may be explained by the strong induction of Axl in the presence of pro-inflammatory cytokines such as interferon-γ, leading to engagement of Axl-dependent phagocytosis ([@B158]), which, in contrast to Mer, is not mediated by protein S.

Regulation of AC Phagocytosis by Other Nuclear Receptors {#s8}
========================================================

Activation of the nuclear receptors, LXR, and the peroxisome proliferator-activated receptors (PPAR) γ and δ also upregulates AC phagocytic capacity ([@B2]), providing a mechanism for sensing the uptake of apoptotic material and enhancement of the phagocytic capacity accordingly. Specific deletion or downregulation of LXRα/β ([@B1]) and PPARδ and retinoid X receptor markedly reduces phagocytosis efficiency ([@B109]). As described for glucocorticoids above, LXR agonists were found to induce expression of Mer leading to augmentation of phagocytosis ([@B1]). Regulation of macrophage inflammatory pathways by the LXR agonist GW3965 significantly attenuated the clinical and histological severity in a model of collagen-induced arthritis in mice ([@B123]). Inflammatory mediator production within the joint and serum pro-inflammatory cytokine levels were inhibited, raising the possibility that targeting LXR may represent a therapeutic target to reduce the severity of joint destruction in rheumatoid arthritis.

Inhibition of PPAR-γ, using the antagonist GW9662, inhibited LPS-induced IL-10 production and decreased AC phagocytosis, in part *via* downregulation of the key phagocytic receptors CD36, transglutaminase-2, and Axl ([@B98]; [@B159]). Antagonism of PPAR-γ was also found to promote macrophage differentiation and upregulation of Mer-dependent AC phagocytosis. In contrast, upregulation of Mer expression was blocked by the PPAR-γ agonist rosiglitazone, suggesting that PPAR-γ negatively controls the expansion of anti-inflammatory macrophages that exhibit efficient AC phagocytosis ([@B159]).

Phagocyte PtdSer and Engulfment {#s9}
===============================

It is well established that PtdSer exposure on the AC surface represents a near universal cue that signals phagocyte recognition ([@B141]). However, transient exposure of PtdSer on the [phagocyte]{.ul} membrane facilitates phagocytosis *via* alteration of the local membrane environment. Callahan and co-workers showed that Annexin V and the lipid binding dye merocyanine (that binds strongly to AC) also bound specifically to non-apoptotic macrophages ([@B17]), a finding also confirmed in *C. elegans* ([@B99]). Redistribution of PtdSer to outer leaflet is promoted by the ATP binding cassette transporter ABCA1 ([@B101]), and ABCA1-deficient cells are less efficient phagocytes ([@B62]). Uptake of ACs also acts to provide a positive amplification loop, inducing expression of ABCA1 *via* LXR-dependent and -independent pathways ([@B44]; [@B74]) leading to further increase of cholesterol efflux. Lyso-PtdSer induced G2A receptor signaling in macrophages to enhance production of prostaglandin E2 (PGE2), activation of EP2 receptors, and adenylate cyclase resulting in cAMP elevation and Rac activation ([@B48]). This effect was dynamic, with low levels of cAMP augmenting phagocytosis of AC, whereas high levels were inhibitory, in keeping with previously published work ([@B131]).

Extracellular Vesicles and Regulation of AC Phagocytosis {#s10}
========================================================

A role for extracellular vesicles (EV) in phagocyte exposure of PtdSer was suggested by studies in *C. elegans* where Ced-7, TTR-52 (PtdSer binding protein), and Ced-1 were required ([@B99]). Vesicles derived from AC (apoEV) may have multiple immunomodulatory effects ([@B95]) that may be dependent on the specific membrane composition and vesicle contents, or cargo ([@B20]). EV originating from different cellular sources may have distinct surface profiles that exert differential effects on macrophage function. It has been shown that apoEVs may facilitate AC phagocytosis by presentation of molecules such as ICAM-3 that specifically direct the recruitment of phagocytes ([@B151]). Exposure of PtdSer on the EV surface allows engagement of receptors involved in AC uptake ([@B108]), including the Axl-Gas6 pathway for platelet-derived EV ([@B65]). Phagocytosis may be further augmented in the presence of apoEV, suggesting that EV exert direct regulatory effects on macrophage functional activity ([@B30]). It is now clear that EV exert control of macrophage function that may critically determine the course of an inflammatory response. In addition, the inflammatory microenvironment may critically determine macrophage responses to EV. Type I interferons were reported to promote phagocytosis of apoEV, leading to acquisition of a pro-inflammatory macrophage phenotype ([@B113]). Interaction of phagocytes with EV derived from non-activated neutrophils was shown to inhibit pro-inflammatory cytokine production ([@B36]), contrasting the potentially pathogenic effects of EV derived from activated neutrophils ([@B56]). Specific EV contents could further regulate reprogramming of macrophage behavior as found for platelet-derived EV delivery of miR126 ([@B82]). Finally, it has been shown that apoEV may acquire distinct lipid profiles by binding to specialized pro-resolving mediators, including RvD1 ([@B25]). This distinct lipid profile was shown to increase macrophage phagocytosis in a GPCR-dependent manner, *via* a mechanism that involves production of RvD2, MaR1, PGE2, and PGF2 by macrophages ([@B25]).

Other Factors {#s11}
=============

In general terms, the capacity for macrophage phagocytosis of different particles is dependent on target size and the presence of opsonizing ligands, including antibodies or serum factors ([@B18]). Early studies suggested that for macrophage phagocytosis of AC, prior uptake inhibited further phagocytic capacity ([@B39]) possibly as a result of reduced membrane availability following internalization of a large AC target. The source of lipids that macrophages utilized for uptake of multiple targets ([@B55]) was proposed to be the endoplasmic reticulum ([@B34]), but this was not confirmed in subsequent detailed studies ([@B152]). Continued uptake of AC by phagocytes may depend on metabolic status. For example, reduced mitochondrial membrane potential was found to increase phagocytic capacity, with a pivotal role for the Ucp2 protein ([@B120]). In *Drosophila melanogaster*, fragments of ACs were shown to enhance subsequent AC phagocytosis. The mechanism appeared to involve activation of Tailless upregulation of Draper and PS3 integrin to enhance phagocytic activity ([@B114]). It is now clear that phagocytosis of AC also causes intracellular changes that impact upon macrophage function. Macrophages taking up AC were found to have reduced mitochondrial length, with increased expression of molecules involved in regulating mitochondrial fission, such as Drp1 ([@B157]). In drp1−/− macrophages, early ingestion of ACs was found to be unaffected, but later AC phagocytosis was reduced compared to control. Since Drp1 inhibition also reduced AC phagocytosis at later timepoints, mitochondrial fission was suggested to enable multiple AC uptake. In the absence of mitochondrial fission, AC induced Ca^2+^ responses are impaired, reducing subsequent phagosome formation ([@B157]).

Negative Regulators {#s12}
===================

Phagocytosis of AC is critically dependent on the balance of activity of the Rac/Rho/cdc42 family of small GTPases. Macrophages actively extend actin-rich processes to "explore" their surroundings ([@B43]). There is some evidence that Rho and Rac may be inversely co-regulated in phagocytes. Whereas RhoA negatively regulates phagocytosis of AC, Rac-1 activation enables efficient uptake, leading to formation of phagocytic "portals" ([@B112]). These AC portals, often associated with lamellipodia, allow multiple targets to be internalized at the same site. However, constitutive Rac1 activation delays phagocytic cup closure and inhibits phagocytosis. Downregulation of CD47 provides a mechanism to promote phagocytosis of ACs ([@B85]). Expression of CD47 on viable cells acts to inhibit phagocytosis by binding to the counter-receptor SIRPα expressed on the phagocyte membrane ([@B154]; [@B94]). SIRPα-dependent activation of the tyrosine phosphatase SHP1/2 signaling results in inhibition of Rac1 activation ([@B118]). This mechanism for prevention of phagocytosis of viable cells by negative regulators such as CD47 should represent an important control pathway in tissue homeostasis. However, mice lacking CD47 exhibit enhanced susceptibility to infection and reduced recruitment of granulocytes ([@B90]); no other major phenotype was noted. It appears that the CD47-SIRPα regulatory pathway is indispensable for controlling the extent of self-phagocytosis in a tissue environment where pro-inflammatory conditions drive macrophage phagocytic responses ([@B11]). Therapeutic targeting of the CD47 pathway may be particularly important in diseases where phagocytosis of AC has been compromised. For example, antibody-mediated blockade of CD47 was found to restore defective AC clearance in atherosclerotic lesions, resulting in reduced atherosclerotic burden ([@B76]). Since elevated expression of CD47 on tumor cells may promote tumor growth by providing an immune escape mechanism, blocking the CD47 pathway may provide a strategy for driving phagocyte destruction of tumor cells ([@B102]).

Therapeutic Implications {#s13}
========================

In health, non-internalized AC are present at very low levels within tissues ([@B72]) suggesting that AC clearance capacity is matched to the overall tissue load of AC. Following injury or infection, imbalances between the rates of apoptosis and phagocytic clearance would result in accumulation of AC within tissues. Although the presence of AC may be a normal feature of physiological responses to tissue injury, AC may eventually undergo secondary necrosis and contribute to perpetuation of inflammatory responses associated with disease. Although therapeutic strategies targeting the apoptotic process may be sufficient to drive resolution of inflammation ([@B19]), modulation of phagocytosis of AC may provide additional options for promotion of repair and restoration of tissue homeostasis following injury or infection. One potential mechanism for regulating phagocytosis of cells would be downregulation of "don't eat me" signals on AC targets ([@B9]). However, given the potential for off-target effects, we will instead consider the potential for exploiting the regulatory mechanisms controlling AC phagocytosis.

First, the differentiation/activation status of macrophages present at inflamed sites could be altered to induce expression of pro-phagocytic receptors. For example, treatment with glucocorticoids ([@B104]) or LXR agonists ([@B1]) would upregulate expression of receptors that are involved in AC clearance such as Mer ([@B130]) and hence promote phagocytic clearance of AC. An alternative approach might be to exploit miRNA that specifically regulates phagocytic receptors. [@B81] showed that miR-34 acted to reduce expression of Axl, and that targeting miR-34 reduced pro-inflammatory cytokine production and dendritic cell activation in mice ([@B81]). The availability of ligands that allow "bridging" of phagocytes to AC targets may be critical. For example, protein S likely represents a key mechanism for reprogramming macrophage maturation, with increased pro-inflammatory mediators (TNF) and reduced anti-inflammatory mediators RvD1 and IL-10 in the protein S-deficient mice ([@B93]). In terms of therapy, overexpression of the Mer ligands protein S and Gas-6 has been shown to reduce inflammation (ankle swelling, pro-inflammatory cytokine levels) in a collagen-induced model of arthritis in mice ([@B155]). Exogenous administration of AC bridging ligands might have therapeutic benefit in a range of inflammatory diseases.

Second, the action of proteases that regulate the expression of phagocytic receptors could be blocked. Inhibitors of ADAM-17 or MMP9 would be predicted to reduce proteolytic downregulation of Mer, LRP1, SRB-1, or CD36 shedding that is associated with reduced capacity for phagocytosis of AC and development of disease, for example in atherosclerotic lesions ([@B29]). In diabetic mice, high levels of glucose downregulated MiR-126 leading to increased expression of ADAM9 and suppression of Mer-dependent phagocytosis of AC ([@B146]). Overexpression of miR-126 conferred rescue of phagocytic defects in response to environmental conditions that suppress AC phagocytosis, such as high glucose ([@B146]).

Third, stimulation of GPCRs mediating the effects of pro-resolving mediators may provide a rapid mechanism for the regulation of phagocytosis of AC.

Finally, microvesicles with defined membrane lipids or protein repertoires may represent a useful mechanism for the modulation of macrophage function ([@B61]). Microvesicles that express accessible PtdSer might be opsonized with PtdSer bridging ligands or specialized pro-resolving mediators, providing a combination of signals that mimics the AC surface. Such tailored microvesicles could be administered directly to sites of injury or inflammation and act to promote acquisition of a macrophage phenotype that is pro-resolution.

In summary, AC clearance is a key process in the control of tissue repair and regeneration. Strategies to overcome defective clearance of apoptotic material could provide new approaches to treating established inflammatory or autoimmune diseases.
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